Articoli. 2) C.M. Foggi, O. Martelli: La terapia adiuvante in oncologia Medicina Ospedaliera, Vol 3 numero 1, Gennaio- Marzo 1999

Transcript

1 Articoli 1) Italian Group for Antiemetic Research (F.Roila, E.Ballatori, V.De Angelis, M.Tonato, A.Del Bavero, G.Ciccarese, O.Martelli et al.): Double- blind, dose- finding study of four intravenous doses of dexamethasone in the prevention of cisplatin- induced acute emesis. Journal of Clinical Oncology, Vol.16, No 9, 1998: ) C.M. Foggi, O. Martelli: La terapia adiuvante in oncologia Medicina Ospedaliera, Vol 3 numero 1, Gennaio- Marzo ) Pierelli L, Leone G, Cortesi E, Martelli O, Perillo A, Mancuso S, Scambia G. Docetaxel and epirubicin plus G- CSF mobilize hematopoietic progenitors in breast cancer Ann Oncol Dec;10(12): ) Italian Group for Antiemetic Research (F.Roila, E.Ballatori, V.De Angelis, M.Tonato, A.Del Bavero, G.Ciccarese, O.Martelli et al.): Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy New England journal of medicine 342(21), (2000) may 25 5) O. Martelli, L Coppola, A.L. De Quarto, M. Palma, R. Sarmiento, C.M. Foggi Fulminant hepatic failure caused by diffuse intrasinusoidal metastatic liver disease: a case report Tumori 86 (5): , ) A Fattorossi, A Battaglia, L Pierelli, P Mlinconico, L Andreocci, A Perillo, G Ferrandina, O Martelli, A Rughetti, M Nuti, E Cortesi, G Scambia: Effects of G- CSF and GM- CSF administration on T cell proliferation and phagocyte cell- surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation Cancer Immunol Immunother, 2001, 49: ) E. Cortesi, O. Martelli, A. Padovani: Ruolo della chemioterapia intraperitoneale Minerva ginecologica vol. 53 suppl 1 n 1, Febbraio ) L. De Rosa, M. Lalle, A. Perillo, L. Pierelli, M.G. Salerno, E. Cortesi, O. Martelli, A. Pandolfi, R. Amodeo, L. Marzetti, S. Mancuso, G. Scambia: Docetaxel and epirubicin plus g- csf as mobilizing treatment to support high- dose chemotherapy in breast cancer Anticancer Research 21: , ) F De Marinis, F. Nelli, O. Martelli, L. Paoluzzi, M. Rapisarda, A. Petroianni: Docetaxel: suo impiego nel trattamento del carcinoma polmonare nsclc 1

2 Tumori 87 Suppl 1 (3): S35-36, May- June ) F. De Marinis, F. Nelli, O. Martelli, L. Paoluzzi, A. Petroianni, M. Rapisarda: Il trattamento nel carcinoma localmente avanzato/metastatico Rassegna di Patologia dell apparato Respiratorio, Vol 16/S- 5: , June ) F. De Marinis, F. Nelli, O. Martelli, L. Pauluzzi, A. Petroianni, M. Rapisarda: Il trattamento nel carcinoma localmente avanzato/metastatico In Gemcitabina soluzioni terapeutiche personalizzate per il paziente affetto da tumore polmonare non microcitoma Simposio Satelllite - XXXVI Congresso Nazionale AIPO Rimini Giugno ) F. De Marinis, F. Nelli, O. Martelli: Il trattamento del carcinoma polmonare non microcitoma avanzato: l efficacia dei nuovi farmaci In Il cancro del polmone Il mesotelioma pleurico Congresso Nazionale FONICAP Cagliari 2001, pp ) F De Marinis, O Martelli, F Nelli, L Paoluzzi: Combinazione di chemioterapia con o senza cisplatino. Regimi a due o tre farmaci Medical International Review Anno V, n 5/ ) F De Marinis, O Martelli, L Paoluzzi: La chemioterapia del microcitoma polmonare: attuali strategie di trattamento Rassegna di oncologia toracica 16/S- 11 Dicembre ) M. R. Migliorino, F De Marinis, F Nelli, F Facciolo, M V Immaturo, A Cipri, R Belli, O Ariganello, F Diana, M Di Molfetta, O Martelli: A 3 week schedale of Gemcitabine plus cisplatin as induction chemotherapy for stage III NSCLC Lung Cancer Vol 35, 2002, ) F. De Marinis, O. Martelli. L. Paoluzzi, F. Nelli, R. Montanaro: Attuali prospettive nel trattamento del carcinoma polmonare a piccole cellule Volume Educazionale IV Congresso Nazionale AIOM Torino settembre 2002 pp ) F. De Marinis, P F Conte, M Rinaldi, a Chella, A Scanni, E Bongiorni, L Portatone, F. Nelli, O. Martelli et al : Docetaxel in metastatic NSCLC pts who failed previous chemotherapy regimens. A first Italian multicenter phase II study (Taxit 206) Rassegna di Patologia dell apparato Respiratorio, Vol 17/5: , Ottobre ) F De Marinis, M R Migliorino, L Paoluzzi, L Portalone, o Ariganello, E Cortesi, T Gamucci, S Gasperoni, A Cipri, O Martelli, F Nelli: Phase I/II trial gemcitabine plus cisplatin and etoposide in patients with small- cell lung cancer Lung Cancer Vol 39, 2003, ) F De Marinis, O Martelli, A Mancuso: 2

3 Combined Chemotherapy and radiation in locally advanced NSCLC Tumori supplemento Vol 2, No 4: S99-102, ) F De Marinis, O Martelli: Qualità of life in lung cancer. Tumori Supplementi Vol 2, No 1: S19-20, ) F De Marinis, O Martelli et al: Gemcitabine, paclitaxel and cisplatin as induction chemotherapy for pts with biopy- proven stage III (N2) NSCLC: a phase II multicenter study Cancer,2003, Vol 98 n 8, ) M Di Maio, F Perrone, C Gallo, RV Iaffaioli et al In List of coauthors O. Martelli. Supportive care in patients with advanced NSCLC. British Journal of Cancer, 2003, 89, ) F Cappuzzo, F De Marinis, F Nelli, C Calandri, A Maestri, G Benedetti, O Martelli, M Andruccetti, S Bartolini, L Crinò. Phase II study of Gemcitabine- cisplatin- paclitaxel triplet as induction chemotherapy in inoperable, locally advanced NSCLC. Lung Cancer, 2003, 42, ) C Gridelli, A Ardizzoni, T Le Chevalier, C Menegold, F Perrone, N Thatcher, N van Zandwijk, M Di Maio, O Martelli, F De Marinis. Treatment of advance NSCLC patients with ECOG PS 2: results of an European Experts Panel. Annals of Oncology 15, , ) Maione P, Perrone F, Gallo C, Martelli O et al. Treatment quality of life and functional status assesment significantly predict survival of elderly patients with advanced NSCLC receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. Journal of Clinical Oncology, Vol.23, No 28, 2005: ) De Petris L, Migliorino MR, Ceribelli A, Martelli O, Di Molfetta M, Mancuso A, De Santis S, Di Salvia R, De Marinis F. Docetaxel administered every two weeks as second- line chemotherapy for advanced non- small cell lung cancer: a phase II study. Anticancer Res Nov- Dec;25(6C): ) Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, De Marinis F, Ardizzoni A. Short hydration regimen and nephrotoxicity of intermediate to high- dose cisplatin- based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori Mar- Apr;93(2): ) C Gridelli Gallo C et al In List of coauthors O. Martelli. 3

4 Factorial phase III randomized trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced NSCLC. The gemcitabine coxib in NSCLCC (GECO) study. Lancet Oncol Jun;8(6): ) Garassino MC, Farina G, Rossi A, Martelli O, Torri V. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol May 20;26(15):2600; author reply ) Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res May- Jun;28(3B): ) Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta- analysis. Anticancer Res Jul;29(7): ) Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM). Off- label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. Tumori Nov- Dec;95(6): ) Gabriella Farina, Flavia Longo, Olga Martelli, Ida Pavese, Andrea Mancuso et al. Rational treatment and study design of TAILOR: a randomized phase III trial of second- line erlotinib versus docetaxel in the treatment of patients affected by advanced non- small cell lung cancer and with the absence of EGFR mutations. Clin Lung Cancer Mar;12(2): ) Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, Elena Collovà, Jessica Menisc,Silvia Novello, Emilio Bria, on behalf of ISA Co- Authors Italian Survey on adjuvant treatment of non- small cell lung cancer (ISA) Lung Cancer Volume 73, Issue 1, Pages 78-88, July ) Marina C Garassino; Valter Torri; Giovanni Michetti; Monica Lo Dico; Nicla La Verde; Stefania Aglione; Andrea Mancuso; Elisa Gallerani; Domenico Galetta; Olga Martelli et al. Outcomes of Small Cell Lung Cancer patients treated with second- line chemotherapy: A multiinstitutional retrospective analysis. Lung Cancer Volume 72,Pages ,

5 36) Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E. Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res May 6;30:50. doi: / Review 37) Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A. Rationale for treatment and study design of tailor: a randomized phase III trial of second- line erlotinib versus docetaxel in the treatment of patients affected by advanced non- small- cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer Mar;12(2): doi: /j.cllc Epub 2011 Apr 11 38) Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM. Carboplatin- or cisplatin- based chemotherapy in first- line treatment of small- cell lung cancer: the COCIS meta- analysis of individual patient data J Clin Oncol May 10;30(14): doi: /JCO Epub 2012 Apr 2. Review. 39) Rossi A, Martelli O, Di Maio M. Treatment of patients with small- cell lung cancer: from meta- analyses to clinical practice. Cancer Treat Rev Aug;39(5): doi: /j.ctrv Epub 2012 Oct 18. Review 40) Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Erlotinib versus docetaxel as second- line treatment of patients with advanced non- small- cell lung cancer and wild- type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol Sep;14(10): Doi: /S (13) Jul 22. Epub 5